375823-41-9 (托珠单抗,Tocilizumab)

托珠单抗;

Tocilizumab;Actemra;Actemra 200;Atlizumab;MRA;R 1569;RoActemra;KBio1_001431;DTXSID10859420;HMS3426I09;AKOS025244084;SB17273;KBio2_005590;HMS3654D04;DB-030329;Spectrum_001148;(resveratrol);KBio3_000848;CHEMBL2019155;DB-072954;KBioGR_002457;DivK1c_006487;KBio3_002965;SPBio_002356;NS00010180;Spectrum3_001821;(Cis-Trans)-Resveratrol;KBio2_001628;NS00096464;SpecPlus_000391;HMS3871F03;KBio3_000847;HMS3267J06;SY014849;1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-;Prestwick1_000508;LUKBXSAWLPMMSZ-UHFFFAOYSA-N;HMS3394I09;DB-139429;Q60998680;5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol;KBio2_003022;MolMap_000045;KBioGR_000454;KBioSS_001628;NCI60_002840;Spectrum2_001497;Bio2_000397;SPBio_001513;KBioSS_000454;Oprea1_727238;375823-41-9;5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol;Prestwick0_000508;KBio2_004196;KBio2_000454;NCGC00017352-23;Bio2_000877;1,3-Benzenediol, 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]-;KBio2_006764;SMP1_000257;Spectrum4_001896;

LUKBXSAWLPMMSZ-UHFFFAOYSA-N

1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H

OC1C=C(C=C(C=1)C=CC1C=CC(=CC=1)O)O